Login / Signup

Venetoclax/decitabine for a pediatric patient with chronic myelomonocytic leukemia.

John C MolinaJulie M AsareLaura TuschongRobert R WestKatherine R CalvoRebecca PerskyAlison M BoyceDima A HammoudSteven M HollandDennis D HicksteinNirali N Shah
Published in: Pediatric blood & cancer (2020)
Chronic myelomonocytic leukemia (CMML) is a myelodysplastic syndrome (MDS)/myeloproliferative disorder most commonly seen in the elderly. We describe an adolescent with monosomy 7 CMML presenting as central diabetes insipidus (DI), who was treated with venetoclax and decitabine as a bridge to hematopoietic stem cell transplantation (HSCT). Central DI is a rare manifestation of monosomy 7-associated MDS including CMML, itself a rare manifestation of GATA2 deficiency, particularly in children. Venetoclax/decitabine was effective for treatment of CMML as a bridge to HSCT.
Keyphrases